Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,700 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Sivchev L, Niemann CU, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Manzoor BS, Jawaid D, Emechebe N, Devine J, Boyer M, Runkel ED, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Al-Sawaf O, et al. Among authors: schneider c. Blood. 2024 Oct 31;144(18):1924-1935. doi: 10.1182/blood.2024024631. Blood. 2024. PMID: 39082668 Free PMC article. Clinical Trial.
Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk.
Winkler D, Schneider C, Zucknick M, Bögelein D, Schulze K, Zenz T, Mohr J, Philippen A, Huber H, Bühler A, Habermann A, Benner A, Döhner H, Stilgenbauer S, Mertens D. Winkler D, et al. Among authors: schneider c. Haematologica. 2010 Nov;95(11):1880-8. doi: 10.3324/haematol.2010.025734. Epub 2010 Aug 16. Haematologica. 2010. PMID: 20713460 Free PMC article.
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S. Steinbrecher D, et al. Among authors: schneider c. Leuk Lymphoma. 2018 Jul;59(7):1614-1623. doi: 10.1080/10428194.2017.1390236. Epub 2017 Oct 24. Leuk Lymphoma. 2018. PMID: 29063805 Clinical Trial.
IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.
Wagener R, López C, Kleinheinz K, Bausinger J, Aukema SM, Nagel I, Toprak UH, Seufert J, Altmüller J, Thiele H, Schneider C, Kolarova J, Park J, Hübschmann D, Murga Penas EM, Drexler HG, Attarbaschi A, Hovland R, Kjeldsen E, Kneba M, Kontny U, de Leval L, Nürnberg P, Oschlies I, Oscier D, Schlegelberger B, Stilgenbauer S, Wössmann W, Schlesner M, Burkhardt B, Klapper W, Jaffe ES, Küppers R, Siebert R. Wagener R, et al. Among authors: schneider c. Blood. 2018 Nov 22;132(21):2280-2285. doi: 10.1182/blood-2018-03-842088. Epub 2018 Oct 3. Blood. 2018. PMID: 30282799 Free PMC article.
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S. Scheffold A, et al. Among authors: schneider c. Blood. 2019 Aug 8;134(6):534-547. doi: 10.1182/blood.2018881029. Epub 2019 Apr 22. Blood. 2019. PMID: 31010847 Free PMC article.
Targeted therapy in CLL: changing the treatment paradigm.
Schneider C, Steinbrecher D, Stilgenbauer S. Schneider C, et al. Oncotarget. 2019 Jun 18;10(40):4002-4003. doi: 10.18632/oncotarget.26964. eCollection 2019 Jun 18. Oncotarget. 2019. PMID: 31258844 Free PMC article. No abstract available.
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.
Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, V Tresckow J, Lange E, Kiehl M, Dreyling M, Ritgen M, Dürig J, Tausch E, Schneider C, Stilgenbauer S, Wendtner CM, Fischer K, Goede 5th, Hallek M, Eichhorst B. Al-Sawaf O, et al. Among authors: schneider c. Leukemia. 2021 Jan;35(1):169-176. doi: 10.1038/s41375-020-0797-x. Epub 2020 Mar 17. Leukemia. 2021. PMID: 32203141 Clinical Trial.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, Bahlo J, Al-Sawaf O, Ritgen M, Fink AM, Eichhorst B, Kreuzer KA, Tandon M, Humphrey K, Jiang Y, Schary W, Bullinger L, Mertens D, Lurà MP, Kneba M, Döhner H, Fischer K, Hallek M, Stilgenbauer S. Tausch E, et al. Among authors: schneider c. Blood. 2020 Jun 25;135(26):2402-2412. doi: 10.1182/blood.2019004492. Blood. 2020. PMID: 32206772 Free article.
3,700 results